{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-098599","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.530318+00:00","generated_at":"2026-05-23T05:07:20.917462+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IN8bio Announces Preclinical Data from Gamma-Delta T Cell Engager Platform at AACR 2025","bullets":["INB-619 (CD19) and INB-633 (CD33) showed potent dose-related killing of leukemia cells at low picomolar concentrations in preclinical studies.","Platform activated and expanded both Vδ1+ and Vδ2+ T cell subsets, addressing reduced cell counts in cancer patients.","Minimal secretion of cytokines IL-6, IL-10, IL-17a suggests lower risk of cytokine release syndrome versus conventional CD3 TCEs.","CEO William Ho highlighted potential for off-the-shelf, scalable platform to target cancers and autoimmune diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-098599","json":"https://secwatch.observer/filing/0001193125-25-098599.json","markdown":"https://secwatch.observer/filing/0001193125-25-098599.md","text":"https://secwatch.observer/filing/0001193125-25-098599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525098599/0001193125-25-098599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525098599/d788811d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-23T05:07:20.917462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}